[go: up one dir, main page]

WO1993019771A1 - Preparation administrable par voie nasale contenant un facteur de stimulation de colonies granulocytaires - Google Patents

Preparation administrable par voie nasale contenant un facteur de stimulation de colonies granulocytaires Download PDF

Info

Publication number
WO1993019771A1
WO1993019771A1 PCT/JP1993/000368 JP9300368W WO9319771A1 WO 1993019771 A1 WO1993019771 A1 WO 1993019771A1 JP 9300368 W JP9300368 W JP 9300368W WO 9319771 A1 WO9319771 A1 WO 9319771A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
csf
stimulating factor
granulocyte colony
administration
Prior art date
Application number
PCT/JP1993/000368
Other languages
English (en)
Japanese (ja)
Inventor
Yoshiteru Watanabe
Mitsuo Matsumoto
Kazutoshi Maruyama
Hideaki Nomura
Satoshi Akamisaka
Original Assignee
Kirin Brewery Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery Company, Limited filed Critical Kirin Brewery Company, Limited
Publication of WO1993019771A1 publication Critical patent/WO1993019771A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Definitions

  • Sugars include lactose, sucrose, sucrose, fructose, D-sorbitol, D-mannitol, inositol, and sucrose.
  • Minerals include magnesium stearate, calcium phosphate, calcium hydrogen phosphate, magnesium carbonate, sodium chloride, calcium sulfate, and the like.
  • organic acids include succinic acid, tartaric acid, citric acid, fumaric acid, lingic acid, gluconic acid, and glucuronic acid.
  • Cellulose includes microcrystalline cellulose, methylcellulose, ethylcellulose, hydroxyethyl cellulose, hydroxypropylcellulose, carboxypropylcellulose, and carboxymethylcellulose sodium. You.
  • Example Granulocyte colony stimulating factor 0.375 sodium sodium deoxycholate
  • the formulation of the present invention of Example 32 was prepared using a phosphate buffer at a concentration of 10 mM.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Préparation administrable par voie nasale contenant, à titre d'ingrédient actif, un facteur de stimulation de colonies granulocytaires (G-CSF), une protéine physiologiquement active.
PCT/JP1993/000368 1992-03-27 1993-03-26 Preparation administrable par voie nasale contenant un facteur de stimulation de colonies granulocytaires WO1993019771A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7160592 1992-03-27
JP4/71605 1992-03-27

Publications (1)

Publication Number Publication Date
WO1993019771A1 true WO1993019771A1 (fr) 1993-10-14

Family

ID=13465457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1993/000368 WO1993019771A1 (fr) 1992-03-27 1993-03-26 Preparation administrable par voie nasale contenant un facteur de stimulation de colonies granulocytaires

Country Status (1)

Country Link
WO (1) WO1993019771A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022065860A1 (fr) * 2020-09-24 2022-03-31 충북대학교 산학협력단 Préparation pouvant être inhalée comprenant du nafamostat ou du camostat

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01132532A (ja) * 1987-10-15 1989-05-25 Syntex Usa Inc 粉末形態ポリプペチド類の経鼻投与
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
WO1992011022A1 (fr) * 1990-12-25 1992-07-09 Kyowa Hakko Kogyo Co., Ltd. Preparation pharmaceutique destinee a une administration par voie nasale

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01132532A (ja) * 1987-10-15 1989-05-25 Syntex Usa Inc 粉末形態ポリプペチド類の経鼻投与
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
WO1992011022A1 (fr) * 1990-12-25 1992-07-09 Kyowa Hakko Kogyo Co., Ltd. Preparation pharmaceutique destinee a une administration par voie nasale

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022065860A1 (fr) * 2020-09-24 2022-03-31 충북대학교 산학협력단 Préparation pouvant être inhalée comprenant du nafamostat ou du camostat

Similar Documents

Publication Publication Date Title
EP1093818B1 (fr) Preparation en poudre pour administration par les muqueuses
EP0566135A1 (fr) Composition transmucosale contenant un peptide et un dérivé de la cytidine
US20100203014A1 (en) Zwitterionic buffered acidic peptide and protein formulations
EP3603660B1 (fr) Facteur 21 de croissance des fibroblastes humains mutants à action prolongée pour le traitement de la stéatohépatite non alcoolique
JP2006502969A (ja) 内因性性腺刺激ホルモン産生の増強
JP2012001558A (ja) ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物
JPH08245417A (ja) 鼻内投与のための薬学的非無機塩類液剤
JP2000504696A (ja) 安定化された成長ホルモン処方物およびその製造方法
TW202400219A (zh) 用於鼻內給藥的索馬魯肽及其鹽的藥物組合物
EP4464331A1 (fr) Composition pharmaceutique stable d'agoniste de récepteurs, son procédé de préparation et son application
EP0434625B1 (fr) IGF-I pour le traitement des effets secondaires dans le traitement par stéroides
US8058236B2 (en) Aqueous inhalation pharmaceutical composition
JPH10505580A (ja) ムラミルペプチド化合物の使用
US6623732B1 (en) Pharmaceutical formulation for nasal administration
JP2004506017A (ja) 抗真菌剤組合せ使用
WO1993019771A1 (fr) Preparation administrable par voie nasale contenant un facteur de stimulation de colonies granulocytaires
US20090022684A1 (en) Methods for hematopoietic stimulation
KR20220097360A (ko) 수유 개선을 위한 메로토신의 비강내 투여
US20080075691A1 (en) Permucosal Composition and Method of Improving Permucosal Absorption
US6228836B1 (en) Permucous preparation
JPH01501708A (ja) アミノ酸の経鼻投与
WO2024222920A1 (fr) Préparation pharmaceutique pour administration intranasale et son procédé de préparation
JPH05339164A (ja) 経粘膜投与剤
CN103520706A (zh) 口服用重组人血清白蛋白融合蛋白制剂配方、产品及用途
JPH07242562A (ja) 顆粒球コロニー刺激因子含有直腸投与製剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase